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Nosocomial infections with Enterococcus faecalis are an emerging health problem. However, drug efflux pumps contributing to
intrinsic drug resistance are poorly studied in this Gram-positive pathogen. In this study, we functionally investigated seven het-
erodimeric ABC transporters of E. faecalis that are annotated as drug efflux pumps. Deletion of ef0789-ef0790 on the chromo-
some of E. faecalis resulted in increased susceptibility to daunorubicin, doxorubicin, ethidium, and Hoechst 33342, and the cor-
responding transporter was named EfrCD. Unexpectedly, the previously described heterodimeric multidrug ABC transporter
EfrAB contributes marginally to drug efflux in the endogenous context of E. faecalis. In contrast, heterologous expression in
Lactococcus lactis revealed that EfrAB, EfrCD, and the product of ef2226-ef2227 (EfrEF) mediate the efflux of fluorescent sub-
strates and confer resistance to multiple dyes and drugs, including fluoroquinolones. Four of seven transporters failed to exhibit
drug efflux activity for the set of drugs and dyes tested, even upon overexpression in L. lactis. Since all seven transporters were
purified as heterodimers after overexpression in L. lactis, a lack of drug efflux activity is not attributed to poor expression or
protein aggregation. Reconstitution of the purifiedmultidrug transporters EfrAB, EfrCD, and EfrEF in proteoliposomes re-
vealed functional coupling between ATP hydrolysis and drug binding. Our analysis creates an experimental basis for the accu-
rate prediction of drug efflux transporters and indicates that many annotated multidrug efflux pumpsmight be incapable of
drug transport and thus might fulfill other physiological functions in the cell.
The Gram-positive bacterium Enterococcus faecalis is a normalinhabitant of the human gastrointestinal tract (1) and gener-
ally displays low levels of virulence (2). E. faecalis is a facultatively
anaerobic coccus that survives under extreme environmental con-
ditions, including extreme pH and temperature ranges. It fre-
quently acquires antibiotic resistance via horizontal gene transfer
(3). These traits have led to its emergence as a major nosocomial
pathogen associated with serious diseases, such as bacteremia, en-
docarditis, urinary tract infections, and surgical wound infections,
which are difficult to treat with antibiotics (4). Whole-genome
sequencing ofE. faecalisV583, a vancomycin-resistant clinical iso-
late, has revealed that more than one-quarter of the predicted
protein-encoding open reading frames (ORFs) originate from
mobile and exogenously acquired DNA (5). Among the trans-
ferred genes are so-called Van clusters, which confer resistance to
the clinically important antibiotic vancomycin, used to treat
-lactam-resistant E. faecalis (3).
While the mechanisms underlying resistance to -lactams,
aminoglycosides, fluoroquinolones, and vancomycin are well
documented, comparatively little is known about drug efflux
pumps in E. faecalis. The genome of E. faecalis V583 contains 34
genes encoding potential multidrug resistance (MDR) pumps be-
longing to four transporter superfamilies (6). However, their con-
tribution to intrinsic resistance against antibiotics is poorly stud-
ied. In contrast to the closely related genus Enterococcus faecium,
E. faecalis is naturally resistant to quinupristin-dalfopristin, a drug
mixture targeting the ribosome,whichwas developed to treat van-
comycin-resistant enterococci (7). Quinupristin-dalfopristin re-
sistance had been linked to the lsa (ef2720) gene, which is present
in E. faecalis but absent from E. faecium (8). Disruption of lsa in E.
faecalis results in40-fold-increased susceptibility to quinupris-
tin-dalfopristin. This gene encodes two fused nucleotide binding
domains (NBDs), which are typically part of ABC transporters.
However, no open reading frame encoding an ABC transporter
transmembrane domain (TMD), which could work in concert
with Lsa to constitute a drug efflux pump, has been identified thus
far. Recently, the Lsa homologue OptrA—encoded on a large
transferable plasmid—was reported to confer resistance to
linezolid in enterococci (9). In analogy to Lsa, no transmembrane
domain belonging to anABC transporterwas found to be encoded
on the plasmid. A very elegant recent study finally revealed that
Lsa and OptrA belong to the ABC-F subfamily of ATP-binding
cassette proteins, which protect the ribosome from the noxious
effect of antibiotics by displacing the drugs from their target bind-
ing sites (10). Further, the major facilitator superfamily trans-
porter EmeA (EF1078), a close homologue of the well-character-
ized MDR transporter NorA of Staphylococcus aureus, has been
shown, on the basis of experiments performed with a correspond-
ing transporter gene deletion, to mediate basal resistance to
ethidium and norfloxacin in E. faecalis (11). Finally, the heterodi-
meric ABC transporter EfrAB (EF2920–EF2919 [EF2920/19]) has
been proposed to be anMDR pump transporting norfloxacin and
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acriflavine when overexpressed in Escherichia coli (12), but its
functional role in E. faecalis was not experimentally studied by a
respective gene deletion.
ABC exporters are a subclass of ABC transporters found in all
living cells. They are composed of at least four domains: two
TMDs and two NBDs. Bacterial ABC exporters are encoded as
half-transporters containing a TMD fused to anNBD,which form
either homodimers, upon the dimerization of two identical poly-
peptides (e.g., Sav1866, MsbA), or heterodimers, from two differ-
ent polypeptides (e.g., LmrCD, PatAB, TM287–TM288 [TM287/
288]). In contrast, most eukaryotic ABC exporters are encoded on
a single large polypeptide chain (e.g., P-gp, MRP1, CFTR, SUR1).
The architecture of ABC exporters has been characterized by crys-
tal structures of the homodimers Sav1866 (13), MsbA (14),
CmABCB1 (15), ABCB10 (16), and McjD (17) and the het-
erodimers P-gp (ABCB1, MDR1) (18, 19) and TM287/288 (20,
21). The 12 transmembrane helices, 6 from each TMD, are re-
sponsible for substrate recognition and form a substrate pathway
across cellular membranes by alternating between inward- and
outward-oriented states. Conformational transitions between the
states is driven by the binding and hydrolysis of ATP at the NBDs
and is transferred to the TMDs via intracellular loops. The two
NBDs are arranged in a head-to-tail conformation, leading to the
formation of two ATP binding sites at their interface. Homodi-
meric ABC transporters consist of two identical ATP binding sites,
whereas many heterodimeric ABC transporters exhibit asymmet-
ric ATP binding sites. In these heterodimeric ABC transporters,
one nucleotide binding site, called the degenerate site, deviates in
the residues responsible for ATP hydrolysis but is still able to bind
nucleotides tightly (22). The second ATP binding site is canonical
and is thus called the consensus site (20).
Several heterodimeric ABC exporters have been reported to be
involved in multidrug efflux in Gram-positive bacteria. These in-
clude Lactococcus lactis LmrCD (23) and Streptococcus pneu-
moniae PatAB (24, 25). Here we studied seven E. faecalis homo-
logues of LmrCD and PatAB with regard to drug efflux. Among
these seven transporters, EfrAB was the only one that had been
characterized previously as a multidrug efflux pump when ex-
pressed in E. coli (see above) (12).
Functional studies using unmarked gene deletions of the seven
transporters revealed that ef0789–ef0790 is the major heterodi-
meric multidrug ABC exporter of E. faecalis, and its gene product
was dubbed EfrCD. Chromosomal deletion of efrAB revealed
modest susceptibility to acriflavine and ethidium, and overexpres-
sion of efrAB in L. lactis confirmed its activity as amultidrug efflux
pump. Finally, the gene product of ef2226–ef2227was identified as
another novel drug efflux pump and was called EfrEF.
MATERIALS AND METHODS
Bacterial strains, growth media, and chemicals. Enterococcus faecalis
V583 (ATCC 700802) was obtained directly from the American Type
Culture Collection (ATCC). Enterococcus faecalis 4205 is a chloramphen-
icol- and erythromycin-sensitive clinical isolate obtained from the diag-
nostic unit of the Institute ofMedicalMicrobiology, University of Zurich.
The sequence of its 16S rRNA locus has been deposited in GenBank under
accession number KU936078. The 16S rRNA sequence of E. faecalis 4205
is identical to that of E. faecalisATCC 29212 (nomismatches in 1,468 bp).
The closest 16S rRNA sequence not belonging to the species E. faecalis is
that of Enterococcus rivorum (10 mismatches in 1,468 bp), showing that
species determinationwas unambiguous.E. faecalis strains V583 and 4205
were grown in half-strength brain heart infusion (hBHI; Bacto) at 30°C or
42°C for routinemaintenance as well as in cation-supplementedMueller-
Hinton broth (MHB) at 37°C for MIC determination. M9 salts supple-
mented with 0.25% yeast extract and 0.5% glucose (MM9YEG) was used
for the generation of gene deletions (26). L. lactisNZ9000lmrAlmrCD
was grown in M17 supplemented with 0.5% glucose (GM17; Oxoid) at
30°Cwithout shaking.E. coli strainsMC1061 andXL1-Bluewere grown in
Luria broth (LB) at 30°C if they contained plasmids with a temperature-
sensitive origin of replication and at 37°C otherwise. The concentrations
of antibiotics used for plasmid propagation were as follows: chloram-
phenicol, 20 g/ml (E. faecalis), 5 g/ml (L. lactis), or 20 to 25 g/ml (E.
coli); ampicillin, 100 to 120 g/ml (E. coli); erythromycin, 10 g/ml (E.
faecalis) or 5 g/ml (L. lactis). All chemicals and antibiotics were pur-
chased from Sigma-Aldrich.
Homology searchusingproteinBLAST.The six half-transporters LmrC
(CAL96930), LmrD (CAL96931), PatA (NP_359478), PatB (NP_359476),
TM287 (Q9WYC3), and TM288 (Q9WYC4) were used as query se-
quences to search for heterodimeric ABC transporters in Enterococcus
faecalis V583 (taxid 226185) using protein BLAST. Protein hits with an
expect value (E value) smaller than 1E4 were considered homologues.
Furthermore, we restricted our search to heterodimeric transporters,
which are encoded on two adjacent open reading frames harboring a
transmembrane domain (TMD) and a nucleotide binding domain (NBD)
and containing a degenerate and a consensus ATP binding site.
Construction of E. faecalis gene deletion mutants. Gene deletions
were generated using the counterselection strategy based on a dominant
negative mutant of the thymidylate synthase gene, thyA*, in a two-step
recombination mechanism (27). Flanking regions of the genes of interest
(see Fig. 2) were amplified from E. faecalis 4205 and E. faecalisV583 using
primers (see Table S2 in the supplemental material) designed on the basis
of the genome sequence of E. faecalis V583. All primers worked equally
well for E. faecalis 4205, confirming the close sequence relationship be-
tween E. faecalis 4205 and E. faecalis V583 observed for the 16S rRNA
sequence. The two flanking regions were fused by overlapping PCR and
were cloned into the gene deletion vector pCJK245_FX using fragment
exchange (FX) cloning (28). To create the FX-cloning-compatible gene
deletion vector pCJK245_FX, a fragment containing the ccdBmarker and
the two SapI restriction sites was amplified from pINIT_cat (28) with
primers containing an XbaI or NcoI restriction site as an overhang (see
Table S3 in the supplementalmaterial) andwas cloned into pCJK245 (27).
The gene deletion vector pCJK245_FX contains a temperature-sensitive
origin of replication, which permits plasmid replication at 30°C but not at
42°C. The gene deletion vectors were transformed into electrocompetent
E. faecalis cells and were selected for resistance to chloramphenicol at
30°C. Colonies were grown in hBHI in the presence of chloramphenicol at
30°C overnight. This preculture was diluted 1:100 into fresh medium and
was grown at 30°C for 3 h, followed by a temperature shift to 42°C for 2 h
to facilitate the first recombination (integration). Cells were plated onto
hBHI agar plates containing chloramphenicol and 5-bromo-4-chloro-3-
indolyl--D-galactopyranoside (X-Gal) (120 g/ml) and were grown at a
nonpermissive temperature (42°C). In order to facilitate the second re-
combination step, blue colonies of the first recombinants were picked and
were propagated in thymine-poor MM9YEG medium in the absence of
chloramphenicol. In this medium, no growth was expected for cells con-
taining the gene deletion vector due to the dominant negative counterse-
lection marker ThyA*, which dimerizes with wild-type ThyA and blocks
its capability to synthesize thymine. However, counterselection strength
was limited, i.e., all first recombinants grew readily in MM9YEG. Coun-
terselection strength could not be improved by using a chemically defined
medium completely lacking thymine. Therefore, the first recombinants
were screened bymonitoring cell growth (expressed as the optical density
at 600 nm [OD600]) to identify those that grew comparatively slowly in
MM9YEG. Slow-growing clones (20% of 1,000 clones tested) were
streaked out onto MM9YEG agar plates containing X-Gal (120 g/ml)
and were incubated at 30°C. White colonies (in total 600 for the seven
deletion mutants) were screened for gene deletions using colony PCR
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(with GoTaq G2 DNA polymerase; Promega). Genomic DNA was pre-
pared from chloramphenicol-sensitive clones, and PCR amplifications
were performed to confirm gene deletions (Phusion DNA polymerase;
Thermo Fisher Scientific). Although a 1:1 ratio was expected between
mutant and wild-type strains as a result of the second recombination, we
obtained only 5% gene deletions, whereas 95% of strains reverted to wild
type. Finally, we were able to generate markerless gene deletions for the
seven heterodimeric ABC exporters in E. faecalis strain 4205 and to delete
the efrAB and efrCD transporters from the genome of the vancomycin-
resistant E. faecalis strain V583 (see Fig. 2).
MIC determination. The MICs of antibiotics were determined by
broth dilution in microtiter plates. MICs for E. faecalis were determined
according to EUCAST guidelines (29). E. faecaliswas grown to saturation
overnight in cation-supplementedMueller-Hinton broth (MHB), diluted
1:100 in fresh medium, and grown at 37°C for 3 h to reach a cell density
equal to or greater than a 0.5 McFarland standard. The microtiter plates
containing 2-fold serial dilutions of antibiotics in cation-supplemented
MHBwere inoculated with 5 105 CFU/ml. The plates were incubated at
37°C for 18 h. MICs for L. lactiswere determined as described in previous
studies (20, 30). L. lactis cells were grown in GM17 at 30°C to saturation
overnight, diluted 1:100 in fresh medium, and then grown at 30°C for 3.5
h to reach the exponential-growth phase. These cells were used to inocu-
late (1:100) microtiter plates containing drugs and nisin (a nisin-contain-
ing culture supernatant of L. lactis NZ9700 was added to the medium at
1:5,000 [vol/vol]). Inoculated plates were incubated at 30°C for 16 h. The
lowest antibiotic concentration preventing growth was determined to be
the MIC.
Complementation of gene deletionmutants. E. faecalisV583efrCD
and E. faecalis 4205 efrCD were complemented with a plasmid express-
ing wild-type efrCD. As a control, EfrCD was inactivated by the introduc-
tion of an E-to-Qmutation in the consensus site. The ORFs of efrCDwere
amplified with its endogenous promoter (200 bp upstream of the start
codon) (see Table S4 in the supplemental material) and were cloned into
plasmid pMSP3535_FX harboring either an erythromycin (for E. faecalis
4205) or a chloramphenicol (for E. faecalis V583) resistance marker (31).
These two complementation vectors were modified from pMSP3535
(catalog no. 46886; Addgene). To generate pMSP3535_FX_em, the
pMSP3535 vector was amplified with primers containing SapI restriction
sites as overhangs (Table S3 in the supplemental material). This PCR
product was cut with SapI and was ligated with the fragment containing
the ccdB marker and the chloramphenicol resistance gene obtained by
SapI digestion of pREXNH3 (28). Since E. faecalis V583 is resistant to
erythromycin, the resistance gene of pMSP3535_FX_em was exchanged
with a chloramphenicol resistance gene. To this end, pMSP3535_FX_em
was amplified with 5=-phosphorylated primers and was ligated via blunt
ends with the chloramphenicol resistance gene that was amplified from
pCJK245. The chloramphenicol resistance gene was oriented in the same
direction as the erythromycin resistance gene in pMSP3535_FX_em. The
MICs of the complemented strains were determined as described above in
cation-supplemented MHB containing erythromycin or chlorampheni-
col to propagate the plasmids.
Assay for the accumulation of fluorescent dyes. L. lactis NZ9000
lmrAlmrCD cells harboring plasmids encoding the seven transporters
(in their wild-type or inactive E-to-Qmutant forms)were grown inGM17
containing 5 g/ml chloramphenicol at 30°C. Expression was induced at
an OD600 of 0.4 to 0.6 with a nisin-containing culture supernatant of L.
lactis NZ9700 for 1 h (1:1,000 [vol/vol]). Cells were washed and were
resuspended with fluorescence buffer (50 mM KPi at pH 7.0, 5 mM
MgSO4). Cells were adjusted to anOD600 of 0.5 in 2ml fluorescence buffer
andwere energized by adding 0.5% glucose. Nigericin and valinomycin (1
Meach) were added prior to the addition of 2=,7=-bis-(2-carboxyethyl)-
5(6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM) to avoid
changes in BCECFfluorescence as a result of pH changes in the cytoplasm.
The accumulation of 5 M ethidium, 0.5 MHoechst 33342, or 0.2 M
BCECF-AMwas monitored at 25°C for 600 s using an LS-55 fluorescence
spectrometer (PerkinElmer). Excitation and emission wavelengths (with
slit widths given in parentheses) were set at 520 nm (10 nm) and 595 nm
(15 nm) for ethidium, 355 nm (5 nm) and 457 nm (5 nm) for Hoechst
33342, and 502nm(2.5 nm) and 525nm(4.0 nm) for BCECF, respectively
(see Fig. 3 and Fig. S1 in the supplemental material).
Cloning, expression, and purification of transporters in L. lactis.
Enterococcal ORFs were amplified from the genomic DNA of E. faecalis
V583 (Table S4 in the supplemental material), cloned into the pREXNH3
shuttle vector by FX cloning (28), and then subcloned into the
pNZ8048NH3 expression vector via vector-backbone exchange (VBEx)
cloning (32). The inactive E-to-Q mutant was generated by mutating the
conserved Walker B glutamate of the consensus site to a glutamine using
QuikChange site-directed mutagenesis (primer sequences are given in
Table S4). Expression vectors harboring the gene of interest were trans-
formed into electrocompetent L. lactisNZ9000lmrAlmrCD cells (33).
The cells were grown inGM17 and 5g/ml chloramphenicol at 30°C to an
OD600 of 1 and were then induced by adding a nisin-containing culture
supernatant of L. lactis NZ9700 for 4 h (1:5,000 [vol/vol]). Membranes
were prepared by disrupting the cells with aMicrofluidizer processor (Mi-
crofluidics) at 30,000 lb/in2 in phosphate-buffered saline (PBS) buffer
(pH 7.4) containing 15 mM K-EDTA (pH 7.4) and a protease inhibitor.
The supernatant from low-spin centrifugation (8,000  g, 10 min, 4°C)
was supplemented with 30 mM MgCl2 and DNase I (1:1,000 [vol/vol])
and was incubated for 30 min at 4°C. Membranes were collected by high-
spin centrifugation (38,000 rpm, 1 h, 4°C; 45 Ti rotor; Beckman) andwere
resuspended in Tris-buffered saline (TBS) (pH 7.5) containing 10% glyc-
erol. Membranes were solubilized for 2 h using 1% (wt/vol) n-dodecyl--
D-maltoside (-DDM), and unsolubilized material was removed by
high-spin centrifugation. The resulting supernatant was loaded onto a
Ni2	-nitrilotriacetic acid (NTA) column, washed with 50 mM imidazole
(pH 7.5), 200 mM NaCl, 10% glycerol, and 0.03% -DDM, and eluted
with 200mM imidazole (pH7.5), 200mMNaCl, 10%glycerol, and 0.03%
-DDM. Protein dialysis against 20 mM Tris-HCl (pH 7.4), 150 mM
NaCl, and 0.03% -DDM and cleavage of the deca-His tag with 3C pro-
tease were performed simultaneously overnight. The deca-His tag and the
His-tagged 3C protease were removed by Ni2	-NTA chromatography.
The cleaved protein was analyzed by size exclusion chromatography
(SEC) on a Superdex 200 Increase 10/300 GL column in 20 mMTris-HCl
(pH 7.4), 150 mMNaCl, and 0.03% -DDM. The protein concentration
was determined by measuring A280 using a NanoDrop 2000c spectropho-
tometer.
Reconstitution into E. coli polar lipids. E. coli total lipids (Avanti
Polar Lipids) were dissolved in chloroform, washed by adding acetone
while stirring at 4°C overnight, and harvested by centrifugation in glass
vials (3,000 g, 10 min, 4°C). E. coli polar lipids were dissolved in diethyl
ether, and nonsoluble lipids were removed by centrifugation (3,000 g,
10min, 4°C). Diethyl ether was evaporated in a rotary evaporator, and the
E. coli polar lipids were dissolved in chloroform to yield 20 mg/ml. Lipid
mixtures of E. coli polar lipids and L-
-phosphatidylcholine (from egg
yolk; catalog no. P3556; Sigma) were prepared in chloroform at a ratio of
3:1 (wt/wt). Chloroform was removed in a rotary evaporator, and lipids
were suspended in 50 mM K-HEPES (pH 7.0). The suspension was soni-
cated to form small unilamellar vesicles (SUVs). Thawing and flash-freez-
ing fused the SUVs to large multilamellar vesicles (LMVs), which were
extruded 11 times through a 400-nm polycarbonate filter to form large
unilamellar vesicles (LUVs). LUVs were diluted to a working concen-
tration of 4 mg/ml and were destabilized using 5.25 mM Triton X-100
(34). The detergent-purified proteins EfrAB, EfrCD, EfrEF, and
EF0942–EF0941 (EF0942/41) (both wild type and E-to-Q mutants)
were added to the destabilized liposomes at a protein/lipid ratio of
1:100. Four rounds of addition and removal of Bio-Beads (SM-2 poly-
styrene beads; Bio-Rad) were performed to remove detergent mole-
cules. In each round, 200 mg Bio-Beads was added to the reconstitu-
tion reaction mixture. The four rounds consisted of incubation at
room temperature for 30 min, at 4°C for 1 h, at 4°C overnight, and at
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4°C for 1 h, respectively. Bio-Beads were removed by filtration, and
proteoliposomes were harvested (40,000 rpm, 40min, 4°C; 70 Ti rotor;
Beckman). Proteoliposomes were resuspended in 50 mM K-HEPES
(pH 7.0) to obtain a final concentration of 4 mg/ml lipids. Protein
concentrations were determined based on the signal intensity on an
SDS-PAGE gel stained with Sypro Ruby (Molecular Probes) using de-
tergent-purified proteins as a reference. The concentrations of the
detergent-purified proteins were determined by measuring A280 using
a NanoDrop 2000c spectrophotometer.
ATPase activity assay. For the determination of basal ATPase activity,
detergent-purified or reconstituted protein was mixed with 1 mM ATP
and was incubated at 30°C for 15 min. A malachite green–molybdate
solution was added as described previously (21). This solution forms a
complex with the released inorganic phosphate and is detected colori-
metrically by measuring A640. ATPase reactions for detergent-purified
proteins were carried out in 20 mMTris-HCl (pH 7.4), 150 mMNaCl, 10
mMMgSO4, and 0.03%-DDM(see Table 4). For reconstituted proteins,
50 mM K-HEPES (pH 7.0) and 10 mM MgSO4 without the addition of
-DDM was used (see Table 4 and Fig. 5). Daunorubicin, ethidium, and
Hoechst 33342were added at final concentrations ranging from0.1Mto
200 M.
Homology modeling. To generate the homology model of EfrCD, a
multiple-sequence alignment was performed, including (i) the sequences
of the seven enterococcal ABC transporters; (ii) the sequences of LmrCD
and PatAB, used as references for bacterial heterodimeric ABC transport-
ers; and (iii) the sequences of homologous bacterial transporters forwhich
crystal structures are available, namely, TM287/288 (20), Sav1866 (13),
and MsbA (14). The sequence alignment was generated using MAFFT
(35). Figures S3 and S4 in the supplemental material show the final align-
ment for TMDs and NBDs, respectively, color coded according to the
Clustal X color scheme, implemented in Jalview (36). Themodel of EfrCD
was built with Modeler, version 9.15 (37), using the structure of TM287/
288 (20) as a template. Twenty structures were generated and were sorted
according to the Discrete Optimized Protein Energy (DOPE) score and
root mean square deviation (RMSD) values calculated on the 
-carbon
only with respect to the template. Among the 10 best models, the repre-
sentative model was chosen based on visual inspection of the side chain
orientations of critical residues at the NBDs, i.e., the Q-loop glutamine,
the switch loop histidine (or glutamine), and the catalytic residue of the
Walker B motif (either aspartate or glutamate).
RESULTS
Identification of heterodimeric ABC exporters in Enterococcus
faecalis. The genome of Enterococcus faecalis V583 was scanned
for the presence of heterodimeric ABC exporters, which are po-
tentially involved in drug efflux.Heterodimeric ABC exporters are
characterized by two hallmarks, to which we confined our search.
First, they are encoded on two separate genes, each encoding a
half-transporter consisting of one TMD and one NBD which are
adjacent to each other and in some cases even overlap on the
genome. Second, most heterodimeric ABC exporters contain
asymmetric NBDs with a degenerate and a consensus ATP bind-
ing site. Three well-characterized heterodimeric ABC drug ex-
porters, Lactococcus lactis IL1403 LmrCD (23), Streptococcus pneu-
moniae R6 PatAB (25), and Thermotoga maritimaMSB8 TM287/
288 (20), served as query sequences, and each of the six half-
transporters was used to conduct protein BLAST searches.
Genome scanning revealed that an astonishing number of het-
erodimeric ABC exporters—seven—were present in E. faecalis
V583, with high sequence identities of 27 to 43% to each other
(Fig. 1; see also Table S1 in the supplemental material).
Endogenously produced EfrCD mediates pronounced drug
efflux. Unmarked gene deletions were generated by using the
dominant negative mutant of the thymidylate synthase gene,
thyA*, as a counterselection marker (27). Two E. faecalis strains
were used: a clinical strain isolated in-house, called E. faecalis
4205, and the vancomycin-resistant E. faecalis strain V583 (5).
Gene deletions were easier to generate in E. faecalis 4205 than in E.
faecalis V583. Therefore, gene deletions of the seven transporters
were initially made in E. faecalis 4205. Gene deletions were de-
signed such that 95 to 100% of the open reading frames (ORFs)
were deleted (Fig. 2a and b). The deletionswere confirmedbyPCR
amplification from genomic DNA (Fig. 2c). None of the gene
deletion mutants displayed any growth deficiencies (not shown).
MICs for 13 typical drug efflux pump substrates were deter-
mined in liquid culture. Sensitivities to doxorubicin, daunorubi-
cin, Hoechst 33342, and ethidium were increased 32-, 8-, 4-, and
2-fold, respectively, when ef0789–ef0790 was deleted in E. faecalis
4205 (Table 1). The gene product, EF0789/90, was therefore iden-
tified as a multidrug efflux pump in the endogenous context of E.
faecalis. In analogy to EfrAB (12), the transporter was termed
EfrCD (E. faecalismultidrug resistance proteins C and D). Unex-
pectedly, E. faecalis 4205 efrAB had a much less pronounced
phenotype than E. faecalis 4205 efrCD, exhibiting only 2-fold-
reduced resistance to acriflavine and ethidium. A 2-fold reduction
in the MIC of acriflavine was also observed upon deletion of the
ef2226 and ef2227 genes. The corresponding gene product was
named EfrEF. For the other four transporter gene deletions, no
changes in drug sensitivity were detectable. The efrAB and efrCD
genes were also deleted in E. faecalis V583. MIC determination
revealed identical MIC changes for the efrCD gene deletion, indi-
cating that the dominant role of efrCD is observed independently
of the strain. In contrast, MIC determination with E. faecalisV583
efrAB did not confirm the 2-fold-increased susceptibilities to
acriflavine and ethidium observed in the corresponding E. faecalis
4205 efrAB strain, indicating that this transporter plays a rather
limited role with regard to drug efflux in the endogenous context
of different E. faecalis strains.
FIG 1 Phylogenetic tree of heterodimeric ABC transporters. Seven E. faecalis
ABC transporters were aligned with Lactococcus lactis LmrCD, Streptococcus
pneumoniae PatAB, and Thermotoga maritima TM287/288. All ABC trans-
porters contain a degenerate and a consensus ATP binding site.
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FIG 2 Generation of gene deletions in E. faecalis. (a) Genetic environment of a heterodimeric ABC transporter gene cluster (efrCD is presented as an example)
in the context of upstream (ef0786, ef0787) and downstream (ef0791, ef0792) genes. Upstream and downstreamflanking regions (1,000 bp each)were amplified
from genomic DNA (gDNA) and were cloned into the gene deletion vector pCJK245_FX. KO, knockout. (b) Translational products of gene remnants after
transporter gene deletion. (c) Confirmation of transporter gene deletions in E. faecalis by PCR amplification fromwild-type (6,000 bp) andmutant (2,500 bp)
genomicDNAwith primers used to amplify the upstream and downstream regions (5=-FW and 3=-RV [see Table S2 in the supplementalmaterial]). Gene deletions for
all seven heterodimeric ABC exporters were generated in E. faecalis 4205. The two transporter genes efrAB and efrCDwere also deleted in E. faecalis V583.
Hürlimann et al.
5404 aac.asm.org September 2016 Volume 60 Number 9Antimicrobial Agents and Chemotherapy
Complementation and overexpression of efrCD in E. faeca-
lis. E. faecalis 4205 efrCD was complemented with a plasmid
containing efrCD preceded by its endogenous promoter
(pMSP3535_FX_em for E. faecalis 4205; pMSP3535_FX_cat for
E. faecalis V583) (31). As a control, a complementation plasmid
was constructed on which the transporter’s consensus siteWalker
B glutamatewasmutated to glutamine (E512Qmutation in EfrD).
This mutant is not capable of ATP hydrolysis and drug transport.
As expected, themutant transporter was unable to complement E.
faecalis 4205efrCD (Table 2). In contrast, when the gene deletion
strain was complemented with the wild-type transporter, it again
became resistant to daunorubicin and Hoechst 33342. The levels
of resistance to daunorubicin and Hoechst 33342 were twice as
high as those in wild-type E. faecalis 4205 (Table 1). We reasoned
that this was due to transporter overexpression from the comple-
mentation plasmid. Indeed, when we transformed the comple-
mentation vector encoding the wild-type transporter into the
original E. faecalis 4205 strain, we observed the same 2-fold in-
crease in resistance to daunorubicin and Hoechst 33342 over that
of E. faecalis 4205 that did not contain any plasmid (Tables 1 and
2). Using efrCD cloned into pMSP3535_FX_cat, we were able to
complement E. faecalisV583efrCD as well (not shown).We also
attempted to complement E. faecalis 4205 efrAB with efrAB, ei-
ther expressed from the nisin-inducible vector pMSP3535 (31) or
cloned in the context of the native promoter. However, these at-
tempts were not successful, presumably because efrAB was not
expressed from these vectors in E. faecalis.
EfrAB, EfrCD, and EfrEF mediate fluorescent dye efflux
when overexpressed in Lactococcus lactis. The analysis of the E.
faecalis transporter gene deletion mutants does not take into ac-
count the gene expression levels of the ABC transporters under
study. Previous studies on the transcriptional responses of E.
faecalis V583 to chloramphenicol and erythromycin revealed that
in the presence of drugs, only a subset of drug efflux pumps are
upregulated (38, 39). For this reason, some of the transporters we
investigatedmay not be expressed under our experimental condi-
tions, which could explainwhywe did not observe a phenotype for
the majority of the transporter gene deletions. To study the trans-
porters independently of their expression in the endogenous con-
text ofE. faecalis, the seven enterococcal ABC exporters were over-
expressed in L. lactis. E. faecalis and L. lactis both belong to the
lactic acid bacteria and are phylogenetically closely related (40). In
addition, well-established gene expression systems based on the
nisin promoter exist for L. lactis (41), making this bacterium the
ideal expression host for the transporters investigated. The het-
erodimeric ABC exporter LmrCD of L. lactis shares 28 to 59%
sequence identity with the seven enterococcal ABC exporters (Ta-
ble S1 in the supplemental material) and has been shown to trans-
port the fluorescent dyes ethidium, Hoechst 33342, and 2=,7=-bis-
(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester
(BCECF-AM) (30, 42). To exclude any masking of drug efflux by
LmrCD, we performed the experiments in the L. lactis lmrA
lmrCD strain (33). For functional analysis of the seven E. faecalis
transporters, the conserved Walker B glutamate of the consensus
site was mutated to a glutamine (E-to-Q mutant) and served as a
negative control.
By use of washed and glucose-energized L. lactis NZ9000
lmrA lmrCD containing the overexpressed transporters, the
accumulation of the fluorescent multidrug transporter substrates
ethidium,Hoechst 33342, andBCECF-AMwasmonitored. Active
efflux is observed when the increase in the fluorescent signal in
cells expressing the wild-type transporter is slower than that in
cells expressing the inactive E-to-Q mutant. EfrCD was the only
TABLE 1 MICs for E. faecalis 4205 and E. faecalis V583 gene deletion strains
Drug tested
MIC (g/ml)a for:
E. faecalis 4205 E. faecalis V583
Wild type efrAB efrCD efrEF ef0942-ef0941 ef1592-ef1593 ef1733-ef1732 ef2593-ef2592 Wild type efrAB efrCD
Ciprofloxacin 1 1 1 1 1 1 1 1 0.5 0.5 0.5
Norfloxacin 4 4 4 4 4 4 4 4 2 2 2
Ofloxacin 2 2 2 2 2 2 2 2 1 1 1
Gentamicin 16 16 16 16 16 16 16 16 1,024 1,024 1,024
Kanamycin 64 64 64 64 64 64 64 64 1,024 1,024 1,024
Minocycline 16 16 16 16 16 16 16 16 0.125 0.125 0.125
Tetracycline 64 64 64 64 64 64 64 64 0.5 0.5 0.5
Rifampin 4 4 4 4 4 4 4 4 0.5 0.5 0.5
Daunorubicin 16 16 2 16 16 16 16 16 16 16 2
Doxorubicin 128 128 4 128 128 128 128 128 128 128 4
Acriflavine 16 8 16 8 16 16 16 16 16 16 16
Ethidium 16 8 8 16 16 16 16 16 16 16 8
Hoechst 33342 1 1 0.25 1 1 1 1 1 0.5 0.5 0.125
a MICs were determined in cation-supplemented Mueller-Hinton broth after 18 h at 37°C from a minimum of three independent experiments. Differences of2-fold from the
MIC for the wild type are shown in boldface.
TABLE 2 Complementation of E. faecalis 4205 efrCD with a plasmid
producing wild-type EfrCD or the inactive E512Q mutant from the
native promoter
E. faecalis 4205
genotype Complementation
MIC (g/ml)a of:
Daunorubicin Hoechst 33342
efrCD EfrCD 32 2
EfrCD_E512Q 2 0.25
Wild type EfrCD 32 2
EfrCD_E512Q 16 1
a MICs were determined in cation-supplemented Mueller-Hinton broth with 10 g/ml
erythromycin after 18 h at 37°C from a minimum of three independent experiments.
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transporter showing marked transport activity for all three dyes
(Fig. 3). EfrAB and especially EfrEF exhibited strong ethidium
transport and were also capable of Hoechst 33342 transport (Fig.
3). Interestingly, the other four transporters (EF0942/41, EF1592/
93, EF1733/32, and EF2593/92) failed to exhibitmeasurable trans-
port activity for these three typical multidrug efflux compounds
(Fig. S1 in the supplemental material).
Overexpression of EfrAB, EfrCD, and EfrEF in L. lactis con-
fersmultidrug resistance. Further, we investigatedwhether over-
expression of the transporters renders L. lactis NZ9000 lmrA
lmrCD more resistant to drugs and dyes. Overexpression of the
transporter EfrCD resulted in increased resistance to tetracycline,
rifampin, daunorubicin, doxorubicin, acriflavine, ethidium, and
Hoechst 33342 (Table 3). EfrAB and EfrEF exhibited drug efflux
FIG 3 Fluorescent dye transport mediated by EfrAB, EfrCD, and EfrEF. Fluorescence spectroscopy was used to measure the accumulation of ethidium (a),
Hoechst 33342 (b), and BCECF-AM (c) by L. lactis NZ9000 lmrA lmrCD cells expressing the respective wild-type or inactive E-to-Q mutant transporter.
Active efflux manifests in a slower increase of fluorescence.
TABLE 3 Increase in drug resistance upon overexpression of enterococcal transporters in L. lactis
Drug tested
Fold change in MICa with overexpression of:
EfrAB EfrCD EfrEF EF0942/41 EF1592/93 EF1733/32 EF2593/92
Ciprofloxacin 1 1 2 1 1 1 1
Norfloxacinb 1.5 1 2 1 1 1 1
Ofloxacin 2 1 2 1 1 1 1
Gentamicin 1 1 1 1 1 1 1
Kanamycin 1 1 1 1 1 1 1
Minocycline 1 1 1 1 1 1 1
Tetracyclineb 1.5 1.5 1 1 1 1.5 1
Rifampin 1 2 1 1 1 1 1
Daunorubicin 2 16 4 1 1 1 1
Doxorubicin 2 32 8 1 1 1 1
Acriflavine 2 2 4 1 1 1 1
Ethidium 4 4 4 1 1 1 1
Hoechst 33342b 1.5 4 2 1 1 1 1
a Calculated as the MIC for cells expressing the wild-type transporter divided by the MIC for cells expressing the inactive E-to-Q mutant. MICs were determined in GM17, 5 g/ml
chloramphenicol, and 1:5,000 (vol/vol) nisin after 16 h at 30°C from a minimum of three independent experiments.
b MICs were determined using a narrow series of drug concentrations, which allowed the measurement of MIC differences of2-fold.
Hürlimann et al.
5406 aac.asm.org September 2016 Volume 60 Number 9Antimicrobial Agents and Chemotherapy
spectra similar to that of EfrCD but were also capable of exporting
the fluoroquinolones ciprofloxacin (a 2-fold MIC increase was
conferred by EfrEF), norfloxacin (a 1.5-fold MIC increase was
conferred by EfrAB and a 2-fold MIC increase by EfrEF), and
ofloxacin (2-fold MIC increases were conferred by EfrAB and
EfrEF). EfrCD exhibited the strongest phenotype for multidrug
transport, displaying 16-fold and 32-fold increases in theMICs of
daunorubicin and doxorubicin, respectively. This is in agreement
with the observations of the E. faecalis gene deletions and the
transport activity measurements with fluorescent dyes in L. lactis.
With the remaining four transporters, EF0942/41, EF1592/93,
EF1733/32, and EF2593/92, no major MIC changes (2-fold)
were observed for any compound tested. Of note, the 1.5-fold-
increased MIC of tetracycline mediated by EF1733/32, although
reproducibly and accurately measured, was not considered strong
enough to justify the conclusion that this transporter is a drug
efflux pump.
Purification of the seven enterococcal ABC transporters. In-
sufficient overexpression or protein aggregation in L. lactis
NZ9000 lmrA lmrCD could explain why four out of seven
transporters did not exhibit drug transport activities. To explore
this possibility, the seven transporters were overexpressed in, and
purified from, L. lactis via a deca-His tag attached to the N termi-
nus of the first chain of the heterodimeric transporter complex. In
agreement with previous studies on LmrCD (43), PatAB (25), and
TM287/288 (20), the enterococcal transporters were purified as
heterodimers, as judged fromSDS-PAGE (Fig. 4; see also Fig. S2 in
the supplemental material), indicating that a stable heterodimeric
complex was formed between the corresponding half-transport-
ers. The identities of the SDS-PAGE bands corresponding to EfrC
and EfrD (Fig. 4c) were confirmed by matrix-assisted laser de-
sorption ionization—time of flight (MALDI-TOF) analysis (not
shown). Size exclusion chromatography analysis of the Ni2	-
NTA-purified transporters revealed that they elute at a retention
volume of ca. 11 ml, which corresponds to the size of a typical
heterodimeric ABC exporter (44) (Fig. S2). Hence, without any
exception, the transporter complexes appeared to be well folded
and even withstood the protein purification procedure, including
extraction from themembrane by detergent. This provides strong
evidence that in the native context of themembrane, all transport-
ers are correctly assembled, precluding protein aggregation as a
cause for missing transport activity. For all transporters, an inac-
tive E-to-Q mutant was purified and served as a negative control
in the ATPase activity measurements for background subtraction.
The expression levels of the E-to-Qmutants were equal to those of
the wild-type transporters (not shown). A narrow fraction of the
SEC peak eluting at 11 ml was used for the determination of basal
ATPase activity. (Basal activity stands for the ATP turnover of an
ABC transporter in the absence of added substrates.) Except for
EF1592/93, all transporters exhibited basal ATPase activities when
measured in the presence of 1 mM ATP at 30°C. However, the
ATP hydrolysis rates observed differed markedly, ranging from
350 to 12,000 nmol Pi/min/mg of protein (Table 4).
Reconstitution of EfrAB, EfrCD, and EfrEF into proteolipo-
somes. To investigate drug-induced modulation of the ATPase
activity in a native environment, we reconstituted the four trans-
porters EfrAB, EfrCD, EfrEF, and EF0942/41 (for each wild type
and inactive E-to-Q mutant) into proteoliposomes. EF0942/41
was used as a control, because it can bewell expressed and purified
and exhibits basal ATPase activity but does not show multidrug
FIG 4 Expression and purification of EfrCD. (a) L. lactis expression construct containing the deca-His tag and 3C protease cleavage site followed by the ORFs
encoding EfrC and EfrD. (b) Homology model of EfrCD based on the coordinates of TM287/288. EfrC is shown in aquamarine and EfrD in pink, and the
conserved Walker B glutamate (E512) of the consensus site is highlighted as blue sticks. The deca-His tag and 3C protease cleavage site are attached to the N
terminus of EfrC. (c) SDS-PAGE analysis of the different purification steps. Lanes: 1, Ni2	-NTA elution; 2, PD-10 elution; 3, after 3C protease cleavage; 4, after
Ni2	-NTA rebinding; 5, main peak fraction of size exclusion chromatography separation. (d) Size exclusion chromatogram of EfrCD using a Superdex 200
Increase 10/300 GL column. A280 is shown in black and A254 in gray. The main peak, eluting at ca. 11 ml, corresponds to an EfrCD heterodimer.
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efflux activity. Relative to those of detergent-purified proteins, the
basal ATPase activities of reconstituted proteins were decreased
for EfrAB, EfrCD, and EfrEF but were increased for EF0942/41
(Table 4). With the reconstituted transporters, drug-induced
modulation of ATPase activity was measured in the presence of
daunorubicin, ethidium, andHoechst 33342 (Fig. 5). These drugs
and dyes were chosen because they are all transported by EfrAB,
EfrCD, and EfrEF. Multidrug ABC transporters respond in vari-
ous ways to drug addition. There are reports of ATPase activation
and inhibition (45, 46), as well as the occurrence of bell-shaped
curves (47–49). In themajority of ourmeasurements, we observed
bell-shaped curves for the three multidrug transporters. ATPase
inhibition as a result of drug additionwas occasionally observed as
well. Among the multidrug transporters, the magnitude of the
responses differed greatly. Importantly, there were only minor
modulations of ATPase activity for the control protein EF0942/41.
For daunorubicin, a strong response in the form of a bell-
shaped curve was seen for EfrCD, whereas the ATPase activities of
EfrAB and EfrEF declined markedly in the concentration range of
10 to 200M(Fig. 5a). Themarked response for EfrCD correlates
well with its capacity to transport this drug efficiently; uponEfrCD
expression in L. lactis, the MIC of daunorubicin is increased 16-
fold, while expression of EfrAB and EfrEF leads to MIC increases
of 2- and 4-fold, respectively (Table 3). The control protein
EF0942/41 did not respond at all, indicating that there is no non-
specific effect on the ATPase activities of ABC transporters in the
daunorubicin concentration range sampled.
For ethidium, a bell-shaped curve with a large magnitude was
observed for EfrEF, and theATPase activity of EfrABwasmodestly
stimulated in the range of 10 to 100M(P,0.05 for comparison
by t test to the EF0942/41 control for all measurement points in
this range) (Fig. 5b). In contrast, the ATPase activity of EfrCDwas
inhibited in the range of 100 to 200M(P,0.05 for comparison
to EF0942/41 by t test). The differences among the three multi-
drug transporters correlate well with the results of the transport
experiments monitored by ethidium fluorescence (Fig. 3a), in
which EfrEF exhibits the strongest and EfrCD the weakest
ethidium transport activity. However, according toMIC determi-
nations in L. lactis, the three multidrug transporters had equal
abilities to confer ethidium resistance (Table 3).
For Hoechst 33342, all three multidrug transporters exhibited
bell-shaped curves (Fig. 5c). In agreement with its pronounced
transport phenotype in L. lactis as monitored by fluorescence and
MIC determination, EfrCD exhibited distinct stimulation of its
ATPase activity by Hoechst 33342 in proteoliposomes. Maximal
stimulation of 165% for EfrAB was seen at a Hoechst 33342 con-
centration of 20M,while EfrEF had itsmaximumof 130% at 2.5
MHoechst 33342, indicating that EfrEF has a higher affinity for
Hoechst 33342 than EfrAB. This difference in affinity may explain
the slight differences observed between these transporters in the
Hoechst 33342 transport assay based on fluorescence as well as in
TABLE 4 Basal ATPase activities in detergent and proteoliposomes
Transporter
Basal activity (nmol Pi/min/mg of protein) in:
Detergent Proteoliposomes
EfrAB 3,689 61 939 76
EfrCD 2,329 130 549 66
EfrEF 805 11 146 14
EF0942/41 578 9 1,663 137
EF1592/93a 0.3 2.4 NDb
EF1733/32 348 4 ND
EF2593/92 12,146 536 ND
a This purified transporter had no measurable ATPase activity.
b ND, not determined.
FIG 5 Drug-modulated ATPase activities of reconstituted enterococcal ABC
exporters. The ATPase activities of EfrAB, EfrCD, EfrEF, and EF0942/41 were
measured in the presence of daunorubicin (a), ethidium (b), and Hoechst
33342 (c) at drug concentrations ranging from 0.1 M to 200 M. ATPase
activities were normalized to the basal activity of the respective transporter in
the absence of drugs (set at 100%). The error bars correspond to the standard
deviations for three technical replicates. The x axis has a logarithmic scale.
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the resistance assays based onMIC determinations; in both trans-
port assays, EfrEF transported Hoechst 33342 more efficiently
than EfrAB. The ATPase activity of the control transporter
EF0942/41 was not totally insensitive to the addition of Hoechst
33342. We observed a slight stimulation in the range of 20 to 50
M and a distinct decrease in activity at 150 M and 200 M
Hoechst 33342. EF0942/41, therefore, may recognize and trans-
port Hoechst 33342 to some extent, but not sufficiently well to
generate an observable transport phenotype. Alternatively,
Hoechst 33342 may have intercalated into the lipid bilayer of the
proteoliposome and in this manner indirectly influenced the
properties of the transporter by changing the fluidity of the mem-
brane.
It should be noted that with detergent-purified transporters,
the ATPase activity was never seen to be stimulated, but was only
inhibited, in the presence of transporter substrates (not shown).
This indicates that drug modulation experiments need to be car-
ried out in the context of a native lipid bilayer.
DISCUSSION
Can multidrug transporters be identified on the basis of their se-
quences? In this study, we addressed this fundamental question by
characterizing seven heterodimeric ABC exporters of E. faecalis.
According to their entries in the National Center for Biotechnol-
ogy Information (NCBI) database, these enterococcal transport-
ers are all predicted to function as “ABC-typemultidrug transport
systems.” One of them, EfrAB, was previously described as a mul-
tidrug efflux pump when overexpressed in E. coli (12).
We thoroughly investigated the transporters in three comple-
mentary experimental settings. First, gene deletions in E. faecalis
permitted us to study the transporters’ contributions to drug ef-
flux in the native context of this pathogenic bacterium. Second,
overexpression in L. lactis, a closely related cousin of E. faecalis,
permitted us to study the drug efflux capacities of the transporters
independently of gene regulation in the native host. Third, bio-
chemical experiments using purified and membrane-reconsti-
tuted transporters offered clues about the coupling between the
transport substrate binding and ATPase activities of the trans-
porters.
Our analysis revealed that only three of the seven predicted
ABC multidrug transporters transported dyes and drugs that are
recognized by typical drug efflux pumps. This finding, however,
does not exclude the possibility that the remaining four transport-
ers transport drugs that were not part of our screen. Under our
experimental conditions, we found that the product of the ef0789–
ef0790 genes was the major multidrug efflux pump in E. faecalis
among the set of ABC transporters investigated, and we named it
EfrCD. The strong efflux activity and broad substrate spectrum of
EfrCD were confirmed in L. lactis, and the ATPase activity of the
purified and reconstituted transporter is robustly modulated by
the drugs it transports. EfrCD is phylogenetically more closely
related to L. lactis LmrCD (58.6% identity) and S. pneumoniae
PatAB (57.4% identity) than to any of the other six enterococcal
ABC transporters investigated in this study (Fig. 1; also Table S1 in
the supplemental material). It is therefore not surprising that the
substrate spectrum of EfrCD closely resembles that of LmrCD,
which has been shown to confer strong resistance to daunorubicin
and exhibits robust transport of the fluorescent dyes ethidium,
Hoechst 33342, and BCECF-AM (30, 43). PatAB has been shown
to transport acriflavine and ethidium, but in contrast to EfrCD, it
also confers resistance to the fluoroquinolones ciprofloxacin and
norfloxacin (24, 50).
EfrAB was described previously as a drug efflux pump expel-
ling multiple dyes and drugs when overexpressed in E. coli (12).
Interestingly, we found that deletion of the efrAB genes in E. faeca-
lishadonlyminor consequences for the drug susceptibility profile,
affecting resistance to acriflavine and ethidium in the E. faecalis
strain 4205. In agreementwith the findings of Lee et al. (12), EfrAB
transported a large set of drugs upon heterologous overexpres-
sion, including doxorubicin, daunorubicin, acriflavine, ethidium,
and norfloxacin. These observations suggest that EfrAB is poorly
expressed in its native host, E. faecalis, but has the capacity to
pump drugs when overexpressed from a plasmid. In analogy, the
expression of EfrEF must be low in E. faecalis under our experi-
mental conditions, because the corresponding gene deletion re-
sults only in 2-fold-decreased resistance to one of the drugs tested,
namely, acriflavine. When overexpressed in L. lactis, EfrEF exhib-
ited a drug efflux profile very similar to that of EfrAB, with which
it shares a sequence identity of 38.9%. EfrEF was the only trans-
porter exhibiting a drug efflux phenotype for ciprofloxacin, nor-
floxacin, and ofloxacin, and it potentially confers resistance to
these fluoroquinolones when derepressed in E. faecalis by muta-
tions.
The remaining four transporters—EF0942/41, EF1592/93,
EF1733/32, and EF2593/92—were unable to transport any of the
drugs included in this study, even when overexpressed in L. lactis
(an exception is a modest, but reproducibly measured, 1.5-fold-
increased MIC of tetracycline with EF1733/32). We showed that
all transporters can be purified as heterodimers in detergent after
overexpression in L. lactis. Therefore, low expression and/or pro-
tein aggregation can be excluded as reasons for lacking multidrug
transport activity. Moreover, except for EF1592/93, the purified
transporters exhibited basal ATPase activity, providing clear evi-
dence that they undergo the conformational cycling required for
transport. The missing ATPase activity of EF1592/93 may be ex-
plained by inactivation of the transporter in the presence of deter-
gent or the lack of ATPase activity in the absence of the transport
substrate. It is well known that the peptide transporter TAP1/2
strictly requires peptide binding to the TMDs to trigger ATP hy-
drolysis (51).
Our observations suggest that EF0942/41, EF1733/32, and
EF2593/92 (and probably also EF1592/93) likely do not operate as
multidrug efflux pumps, although that is their annotated func-
tion. In agreement with its lack of a drug efflux phenotype, the
ATPase activity of reconstituted EF0942/41 is not modulated by
daunorubicin, ethidium, or Hoechst 33342. In contrast, the
ATPase activities of the verified multidrug transporters EfrAB,
EfrCD, and EfrEF are modulated by their transport substrates
daunorubicin, ethidium, and Hoechst 33342, indicating specific
coupling between the drug binding site at the TMDs and ATP
hydrolysis at the NBDs. Drug-induced ATPase modulation pro-
files manifested mainly as bell-shaped curves. These curves have
been interpreted previously as arising from a sum of stimulating
and inhibiting effects of drug addition. At low drug concentra-
tions, ATPase activity is stimulated due to drug binding to its
high-affinity site. At higher drug concentrations, ATPase activity
decreases again due to the presence of a low-affinity drug release
site, which becomes occupied at elevated drug concentrations,
leading to inhibition of the transport cycle and ATPase activity
(47). We also observed purely inhibitory curves, as, for example,
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for EfrAB in the presence of daunorubicin. In light of their strong
correlation with transport, the ATPase activities of the reconsti-
tuted ABC transporters represent an excellent experimental read-
out for identification of further drug substrates of EfrAB, EfrCD,
and EfrEF.
In summary, our analysis revealed two novel ABC multidrug
transporters of E. faecalis, which—in analogy to the previously
identified transporter EfrAB—were called EfrCD and EfrEF.
Among these three transporters, EfrCD plays themost prominent
role in the native context of E. faecalis, presumably because its
protein production level is highest. On the basis of extensive bio-
chemical experiments, four of seven ABC transporters appear to
be unable to translocate the typical multidrug efflux transporter
drugs included in this study, although they are annotated accord-
ing to their protein sequences as “ABC-type multidrug transport
systems.” It is well documented that multidrug transporters also
recognize endogenous substrates and thereby fulfill physiological
functions in the cell (52). It is therefore likely that the seven trans-
porters recognize substrates other than dyes and drugs and that a
subset—EfrAB, EfrCD, and EfrEF—are, in addition, capable of
extruding drugs. Our analysis provides an excellent starting point
for the identification of critical differences between closely related
transporters, of which only a fraction appear to be capable of
multidrug transport. Molecular hallmarks of drug efflux pumps
are likely to be determined in future studies and will permit reli-
able prediction of drug efflux pumps based on their amino acid
sequences.
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